A rare blood disorder that can emerge months after COVID-19 recovery is gaining attention in medical literature worldwide, with implications for Thailand's millions of former COVID patients. Pure Red Cell Aplasia (PRCA)—a condition where the bone marrow stops producing red blood cells—has been confirmed in multiple post-infection cases, with onset occurring anywhere from 10 to 120 days after initial viral exposure.
Why This Matters
• Delayed onset: Symptoms can appear months after recovery, meaning former COVID patients may not connect fatigue and breathlessness to their past infection.
• Rare but serious: While PRCA is extremely uncommon, untreated cases require frequent blood transfusions and can lead to severe anemia.
• Treatment exists: Immunosuppressive therapy has shown effectiveness, particularly when diagnosed early.
• Local relevance: Thailand's high COVID-19 case count since 2020 means a larger potential pool of at-risk individuals.
What Pure Red Cell Aplasia Actually Does
In a healthy person, the bone marrow continuously generates immature red blood cells called reticulocytes, which mature and carry oxygen throughout the body. PRCA disrupts this assembly line at the earliest stage—proerythroblasts, the very first red cell precursors, disappear almost entirely from the marrow. The result is a steep drop in hemoglobin levels, leaving patients exhausted, pale, and short of breath even during light activity.
Unlike broader bone marrow failure syndromes such as aplastic anemia—which affects white cells and platelets too—PRCA targets red cell production exclusively. This selectivity points to an immune system malfunction rather than generalized marrow damage.
The COVID Connection
Medical literature published through August 2026 documents numerous cases linking SARS-CoV-2 infection to subsequent PRCA onset. The mechanism remains under investigation, but researchers believe the virus triggers an autoimmune cascade. Activated T-lymphocytes—normally tasked with hunting infected cells—mistakenly attack the bone marrow's red cell progenitors, halting production.
One case report from 2025 described the first documented instance of post-COVID PRCA in an HIV-positive patient. That individual required both immunosuppressive drugs and regular transfusions before red cell production resumed. The case underscored that extrapulmonary complications of SARS-CoV-2—those affecting organs beyond the lungs—deserve closer surveillance, particularly in immunocompromised populations.
Other recent reports have flagged potential links between COVID-19 vaccines and PRCA-like syndromes. A 65-year-old man with pre-existing myelodysplastic syndrome developed PRCA two weeks after receiving the Pfizer–BioNTech mRNA vaccine. An 80-year-old developed severe anemia following a heterologous vaccination schedule combining AstraZeneca and Pfizer doses. Both patients responded to treatment with erythropoietin or immunosuppression. While causation has not been established, clinicians are advised to consider vaccine timing when evaluating unexplained anemia in patients with underlying blood disorders.
How Common Is It?
Precise incidence rates remain elusive because PRCA is so rare that population-level data is sparse. For context, aplastic anemia—a broader marrow failure category—occurs in roughly 2 to 4 people per million per year globally. Some regional datasets suggest post-COVID aplastic anemia rates may be several times higher than baseline, though these figures include all forms of marrow suppression, not PRCA alone.
What is clear from case series published in 2025–2026 is that affected patients span a wide age range—28 to 77 years—with a slight male predominance. Most had mild to moderate COVID-19 illness initially and were surprised when anemia symptoms surfaced weeks or months later.
Risk Factors to Watch
While any former COVID patient could theoretically develop PRCA, certain profiles appear more vulnerable:
• Pre-existing autoimmune conditions, such as autoimmune hemolytic anemia
• Hematologic malignancies, including large granular lymphocytic leukemia and thymoma
• Immunodeficiency states, such as common variable immunodeficiency or HIV infection
• Concurrent viral infections, especially Epstein-Barr virus or parvovirus B19
• Recent COVID-19 vaccination in individuals with underlying blood disorders (though this association remains under review)
Treatment Pathways
Hematologists worldwide treating PRCA typically follow a stepwise protocol:
Corticosteroids (prednisone or dexamethasone) serve as first-line therapy to dampen immune overactivity. Response rates vary, and relapse is common.
Cyclosporine (CsA) is the go-to second-line agent, often combined with steroids. Studies show it can reduce transfusion dependence and restore reticulocyte counts.
Tacrolimus offers an alternative immunosuppressive route, especially useful when anti-erythropoietin antibodies are detected in the bloodstream.
Rituximab, a monoclonal antibody, targets B-cells and has proven effective in refractory cases, particularly those linked to lymphoproliferative disorders.
Intravenous immunoglobulin (IVIG) is reserved for third- or fourth-line use, with higher success rates in parvovirus-associated PRCA.
Eltrombopag and sirolimus represent newer options. Eltrombopag stimulates marrow activity, while sirolimus has shown efficacy comparable to cyclosporine in small trials.
Red blood cell transfusions remain essential during the acute phase, buying time while immunosuppressive drugs take effect.
One innovative case involved a dialysis patient with anti-EPO antibodies who responded to roxadustat, an oral medication that mimics the body's low-oxygen response, combined with tacrolimus.
What This Means for Residents
For anyone living in Thailand who contracted COVID-19—whether in 2020, 2023, or more recently—persistent unexplained fatigue, dizziness, or paleness warrants a complete blood count. Don't assume these symptoms are simply post-viral malaise or long COVID if they worsen over weeks.
Bangkok's major private hospitals including Bumrungrad International Hospital, Samitivej Hospital, and BNH Hospital have well-equipped hematology departments capable of performing complete blood counts, reticulocyte testing, and bone marrow biopsies. These institutions typically charge between 2,000-5,000 THB for initial hematology consultations and blood work. Bone marrow biopsy procedures generally cost 15,000-30,000 THB at private facilities. Most international health insurance policies and comprehensive Thai health insurance plans cover these diagnostic services, though it's wise to verify your specific coverage before seeking care.
Expats and foreign residents should ensure their Thai health insurance or international coverage includes hematology consultations and bone marrow biopsy if needed, as definitive PRCA diagnosis requires marrow examination. When discussing symptoms with Thai doctors, reference the medical term "Pure Red Cell Aplasia" and the specific timeline—symptoms appearing 10-120 days post-COVID—as this will help ensure appropriate testing, even if the condition is unfamiliar to your local provider.
For those in provincial areas, referral to a university hospital such as Chiang Mai University Hospital or Prince of Songkla University Hospital in Hat Yai can provide specialized hematology care. These institutions also offer diagnostic capabilities comparable to Bangkok facilities, though at lower costs typical of regional hospitals.
The Bigger Picture
PRCA joins a growing list of delayed COVID-19 complications that include myocarditis, kidney injury, and neurological dysfunction. The fact that symptoms can surface up to four months post-infection complicates both diagnosis and public health tracking. Many patients no longer test positive for the virus by the time blood counts plummet, making clinical history and timeline reconstruction critical.
The condition's recognition in global medical literature—and Thailand's COVID case burden exceeding 4.7 million confirmed infections since the pandemic began—suggests thousands of residents could theoretically be at risk, even if only a tiny fraction ever develop the disorder.
Physicians are encouraged to maintain a high index of suspicion. A simple reticulocyte count—which measures immature red cells—can flag PRCA early. In affected patients, this count drops to near zero despite severe anemia, a hallmark that distinguishes PRCA from iron deficiency or chronic disease anemia.
Prognosis and Recovery
When diagnosed early and treated with appropriate immunosuppression, most PRCA patients achieve full hematologic recovery. The timeline varies: some regain normal red cell production within weeks, while others require months of therapy. Relapse rates are notable, particularly in steroid-only regimens, which is why combination therapy or early escalation to agents like cyclosporine is often favored.
Close monitoring of hemoglobin and reticulocyte levels allows doctors to adjust treatment intensity. Once red cell production restarts—signaled by rising reticulocyte counts—transfusion needs taper off, and patients can gradually resume normal activities.
The key takeaway for both clinicians and the public: PRCA is treatable, but only if recognized. Former COVID patients experiencing worsening fatigue should not hesitate to seek blood testing, and doctors should consider bone marrow evaluation in cases of unexplained anemia with low reticulocyte counts, especially when there is a history of SARS-CoV-2 infection in the preceding months.
